Mandate

Vinge advises Embellence Group AB (publ) in connection with the listing on Nasdaq First North Premier Growth Market

Vinge advises Embellence Group AB (publ) (“Embellence Group”) in connection with the listing on Nasdaq First North Premier Growth Market. The offering circular was published on 15 March 2021 and first day of trading was on 24 March 2021.

The offering price was SEK 42, corresponding to a market value of Embellence Group of approximately SEK 900 million. The offering comprised approximately 10.8 million shares, corresponding to a value of approximately SEK 454 million, provided that the overallotment option is exercised in its entirety.

Embellence Group, founded in 1905 in Borås, Sweden, is a leding European company in interior decoration, with a focus on premium brands within wallpaper, textile, rugs and other interior decoration with sales in over 90 countries. The company’s brand portfolio includes Cole & Son, Wall&decò, Perswall, Pappelina and Boråstapeter.

Vinge’s team mainly consisted of Johan Winnerblad, Jesper Schönbeck, Rikard Lindahl, Joel Magnusson, Linnea Petersson and Louise Brorsson Salomon, Pauline Lagerstrand and Rebecka Målquist regarding financing matters and Mattias Schömer and Henrik Wastenson regarding tax matters.

 

Related

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.
June 20, 2024

Vinge advises Axcel VI and the Currentum in connection with the acquisition of Elektro-Emanuel

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elektro-Emanuel AB. The company carries out electrical installations for both companies and private individuals and has offices in four cities in western Sweden.
June 19, 2024

Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing

Moleculent AB, a company pioneering technology to study the communication between cells in human tissue, has closed its oversubscribed $26 million Series A financing. The round was led by ARCH Venture Partners and co-led by Eir Ventures with participation from the company’s existing investors.
June 19, 2024